用铊-201闪烁扫描术评估化疗对骨肉瘤的疗效。
Thallium-201 scintigraphy to assess effect of chemotherapy in osteosarcoma.
作者信息
Ohtomo K, Terui S, Yokoyama R, Abe H, Terauchi T, Maeda G, Beppu Y, Fukuma H
机构信息
Division of Nuclear Medicine, National Cancer Center Hospital, Tokyo, Japan.
出版信息
J Nucl Med. 1996 Sep;37(9):1444-8.
UNLABELLED
Imaging results in patients with high-grade osteosarcoma of the extremities were reviewed to determine whether scintigraphic appearance correlated with histologic response to preoperative chemotherapy.
METHODS
Histologically, the percent tumor necrosis in specimens from 30 patients were classified into three grades: grade 1 = necrosis less than 60%, grade 2 = 60%-89% necrosis and grade 3 = diffuse necrosis greater than 90% based upon whole transverse sections. Scintigraphically, we analyzed 201TI uptake before and after preoperative chemotherapy. The changes in the tumor-to-background ratio were defined by an alteration ratio.
RESULTS
Of the 11 patients with a grade 1 response, the ratio showed -67.1% +/- 45.4% (mean +/- s.d.). Of the 9 patients with a grade 2 response, the ratio showed 37.9% +/- 29.9% of the 10 patients with a grade 3 response the ratio showed 105.5% +/- 12.4%. The ratios correlated well with the histologic grades (p < 0.0001; analysis of variance).
CONCLUSION
Thallium-201 scintigraphy accurately assesses the effect of chemotherapy on osteosarcoma.
未标记
回顾了四肢高级别骨肉瘤患者的影像学结果，以确定闪烁显像表现是否与术前化疗的组织学反应相关。
方法
组织学上，根据整个横切面，将30例患者标本中的肿瘤坏死百分比分为三个等级：1级=坏死小于60%，2级=坏死60%-89%，3级=弥漫性坏死大于90%。闪烁显像方面，我们分析了术前化疗前后的201铊摄取情况。肿瘤与背景比值的变化由改变率定义。
结果
11例1级反应患者的比值为-67.1%±45.4%（平均值±标准差）。9例2级反应患者的比值为37.9%±29.9%，10例3级反应患者的比值为105.5%±12.4%。这些比值与组织学分级相关性良好（p<0.0001；方差分析）。
结论
201铊闪烁显像能准确评估化疗对骨肉瘤的疗效。
Zotero 插件